Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Dan Legault has been the CEO of Antibe Therapeutics Inc. (CVE:ATE) since 2009. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth that the business demonstrates. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This method should give us information to assess how appropriately the company pays the CEO.
Check out our latest analysis for Antibe Therapeutics
How Does Dan Legault's Compensation Compare With Similar Sized Companies?
According to our data, Antibe Therapeutics Inc. has a market capitalization of CA$80m, and pays its CEO total annual compensation worth CA$273k. (This is based on the year to March 2018). Notably, the salary of CA$273k is the vast majority of the CEO compensation. We examined a group of similar sized companies, with market capitalizations of below CA$264m. The median CEO total compensation in that group is CA$152k.
It would therefore appear that Antibe Therapeutics Inc. pays Dan Legault more than the median CEO remuneration at companies of a similar size, in the same market. However, this fact alone doesn't mean the remuneration is too high. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.
You can see, below, how CEO compensation at Antibe Therapeutics has changed over time.
Is Antibe Therapeutics Inc. Growing?
Over the last three years Antibe Therapeutics Inc. has grown its earnings per share (EPS) by an average of 2.9% per year (using a line of best fit). In the last year, its revenue is up 8.6%.
I would argue that the improvement in revenue isn't particularly impressive, but I'm happy with the modest EPS growth. It's clear the performance has been quite decent, but it it falls short of outstanding,based on this information. You might want to check this free visual report on analyst forecasts for future earnings.
Has Antibe Therapeutics Inc. Been A Good Investment?
Boasting a total shareholder return of 141% over three years, Antibe Therapeutics Inc. has done well by shareholders. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.
In Summary...
We compared total CEO remuneration at Antibe Therapeutics Inc. with the amount paid at companies with a similar market capitalization. We found that it pays well over the median amount paid in the benchmark group.